dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Simon, Maria S. |
dc.contributor.author | Burger, Bianka |
dc.contributor.author | Weidinger, Elif |
dc.contributor.author | Arteaga Henriquez, Gara |
dc.contributor.author | Zill, Peter |
dc.contributor.author | Musil, Richard |
dc.date.accessioned | 2022-05-05T07:43:57Z |
dc.date.available | 2022-05-05T07:43:57Z |
dc.date.issued | 2021-09-27 |
dc.identifier.citation | Simon MS, Burger B, Weidinger E, Arteaga-Henríquez G, Zill P, Musil R, et al. Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial. Front Psychiatry. 2021 Sep 27;12:615261. |
dc.identifier.issn | 2048-8513 |
dc.identifier.uri | https://hdl.handle.net/11351/7480 |
dc.description | Trastorn depressiu major; Tractament antiinflamatori; Citocina |
dc.description.sponsorship | This present work was funded by the EU 7th Framework program (grant number EU-FP7-CP-IP-2008-222963/EU-FP7-PEOPLE-2009-IAPP-MarieCurie-286334) and Horizon 2020 (grant number H2020-SC1-2016-2017/H2020-SC1-2017-Two-Stage-RTD). Further, part of this work was supported by the foundation Immunität und Seele. The funders had no role in the study design, data collection and analysis, or decision to publish. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Psychiatry;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Malalties mentals - Tractament |
dc.subject | Depressius |
dc.subject | Antiinflamatoris |
dc.subject.mesh | Depressive Disorder, Major |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Therapy, Combination |
dc.subject.mesh | Anti-Inflammatory Agents |
dc.title | Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fpsyt.2021.615261 |
dc.subject.decs | trastorno depresivo mayor |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | farmacoterapia combinada |
dc.subject.decs | antiinflamatorios |
dc.relation.publishversion | https://doi.org/10.3389/fpsyt.2021.615261 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Simon MS, Weidinger E, Zill P, Musil R] Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University, Munich, Germany. [Burger B] Marion von Tessin Memory-Center, Munich, Germany. [Arteaga-Henríquez G] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 34646168 |
dc.identifier.wos | 000736068200011 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/FP7/286334 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |